<DOC>
	<DOCNO>NCT02558790</DOCNO>
	<brief_summary>This study 12-week , open-label pilot study test effect MMFS-201-301 cognition function adult ADHD . Subjects may enter trial stable dose medication ADHD , MMFS-201-301 give . Subjects enter stable dose ADHD medication receive MMFS-201-301 alone .</brief_summary>
	<brief_title>Magnesium L-Threonate Supplementation ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Male female adult age 1855 year age A diagnosis childhoodonset Attention Deficit/Hyperactivity Disorder ( ADHD ) , meet Diagnostic Statistical Manual , Fifth Edition ( DSMV ) criteria ADHD adulthood , include least 5 current symptom inattentive impulsivehyperactive trait , childhood onset age 12 , define two symptom inattentive impulsive/hyperactive trait age 12 A score 20 Adult ADHD Investigator Symptom Report Scale ( AISRS ) , , individual stably treat stimulant , Clinical Global Impression ADHD ( CGIADHD ) severity score great 4 ( `` moderately ill '' ) Subjects stable dose stimulant medication must treat dose least 1 month prior study entry A history intolerance magnesium supplementation , ingredient MgT201 Pregnant nursing females A know unstable medical illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include hypertension â‰¥ 140/90 mmHg screen ) , endocrinologic ( e.g . thyroid ) , neurologic ( e.g . seizure ) , immunologic , hematologic , psychiatric ( ADHD ) disorder ) ; individual kidney dysfunction exclude , dysfunctional kidney may difficulty clear magnesium body ( result dangerously high magnesium level ) ; individual heart block exclude study Any medical condition Principal Investigator believe exacerbate study participation A history cancer ( except localize skin cancer without metastasis situ cervical cancer ) within 5 year prior screen A known history narrowangle glaucoma Current ( within 3 month ) DSMV criterion abuse dependence psychoactive substance nicotine Intelligence Quotient le 80 Multiple adverse drug reaction Any concomitant medication primarily central nervous system activity specify study protocol Current use monoamineoxidase inhibitor ( MAOI ) use within past two week Current use antibiotic , study agent may reduce absorption antibiotic Subjects may take follow substance least 7 day prior baseline throughout study : Calcium channel blocker ; psychoactive medication ; medication know interact magnesium ; supplemental magnesium magnesiumcontaining product ; dietary herbal supplement product include purported improve memory , improve sleep , decrease stress . Investigator his/her immediate family ; define investigator 's spouse , parent , child , grandparent , grandchild</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Attention Deficit/Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Attention Deficit Disorder</keyword>
	<keyword>ADD</keyword>
	<keyword>Magnesium</keyword>
</DOC>